US5521184A
(en)
*
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
GB9212673D0
(en)
*
|
1992-06-15 |
1992-07-29 |
Celltech Ltd |
Chemical compounds
|
US6171786B1
(en)
|
1992-09-17 |
2001-01-09 |
Board Of Trustees Of University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
US5972598A
(en)
*
|
1992-09-17 |
1999-10-26 |
Board Of Trustess Of The University Of Illinois |
Methods for preventing multidrug resistance in cancer cells
|
GB9222253D0
(en)
*
|
1992-10-23 |
1992-12-09 |
Celltech Ltd |
Chemical compounds
|
GB9304919D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
GB9304920D0
(en)
*
|
1993-03-10 |
1993-04-28 |
Celltech Ltd |
Chemical compounds
|
WO1995009851A1
(en)
*
|
1993-10-01 |
1995-04-13 |
Ciba-Geigy Ag |
Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
|
US5543520A
(en)
*
|
1993-10-01 |
1996-08-06 |
Ciba-Geigy Corporation |
Pyrimidine derivatives
|
WO1995009847A1
(en)
*
|
1993-10-01 |
1995-04-13 |
Ciba-Geigy Ag |
Pyrimidineamine derivatives and processes for the preparation thereof
|
JP2983636B2
(ja)
*
|
1993-10-01 |
1999-11-29 |
ノバルティス アクチェンゲゼルシャフト |
薬理学的に活性なピリジン誘導体及びその製造方法
|
GB9325217D0
(en)
*
|
1993-12-09 |
1994-02-09 |
Zeneca Ltd |
Pyrimidine derivatives
|
GB9326699D0
(en)
*
|
1993-12-22 |
1994-03-02 |
Celltech Ltd |
Chemical compounds
|
DE69433594T2
(de)
*
|
1993-12-22 |
2004-08-05 |
Celltech R&D Ltd., Slough |
Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
|
US5786354A
(en)
*
|
1994-06-21 |
1998-07-28 |
Celltech Therapeutics, Limited |
Tri-substituted phenyl derivatives and processes for their preparation
|
US6245774B1
(en)
|
1994-06-21 |
2001-06-12 |
Celltech Therapeutics Limited |
Tri-substituted phenyl or pyridine derivatives
|
GB9412573D0
(en)
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412571D0
(en)
*
|
1994-06-22 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
GB9412672D0
(en)
*
|
1994-06-23 |
1994-08-10 |
Celltech Ltd |
Chemical compounds
|
US5756527A
(en)
*
|
1995-06-07 |
1998-05-26 |
Ontogen Corporation |
Imidazole derivatives useful as modulators of multi drug resistances
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526245D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9526246D0
(en)
*
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9608435D0
(en)
*
|
1996-04-24 |
1996-06-26 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0812829A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Substituted imidazoles as modulators of multi-drug resistance
|
EP0812830A1
(en)
*
|
1996-06-14 |
1997-12-17 |
Ontogen Corporation |
Modulators of multi-drug resistances
|
GB9619284D0
(en)
*
|
1996-09-16 |
1996-10-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9622363D0
(en)
*
|
1996-10-28 |
1997-01-08 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9625184D0
(en)
*
|
1996-12-04 |
1997-01-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
EP0946523A1
(en)
|
1996-12-23 |
1999-10-06 |
Celltech Therapeutics Limited |
Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
|
GB9705361D0
(en)
*
|
1997-03-14 |
1997-04-30 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9713087D0
(en)
*
|
1997-06-20 |
1997-08-27 |
Celltech Therapeutics Ltd |
Chemical compounds
|
CO4940418A1
(es)
*
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
GB9914258D0
(en)
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU5889100A
(en)
|
1999-06-30 |
2001-01-31 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
WO2001000207A1
(en)
|
1999-06-30 |
2001-01-04 |
Merck & Co., Inc. |
Src kinase inhibitor compounds
|
ATE253915T1
(de)
|
1999-06-30 |
2003-11-15 |
Merck & Co Inc |
Src-kinase hemmende verbindungen
|
GB9919778D0
(en)
|
1999-08-21 |
1999-10-27 |
Zeneca Ltd |
Chemical compounds
|
JP3892296B2
(ja)
|
1999-09-10 |
2007-03-14 |
メルク エンド カムパニー インコーポレーテッド |
チロシンキナーゼ阻害薬
|
GB9924862D0
(en)
|
1999-10-20 |
1999-12-22 |
Celltech Therapeutics Ltd |
Chemical compounds
|
AU2001237041B9
(en)
*
|
2000-02-17 |
2005-07-28 |
Amgen Inc. |
Kinase inhibitors
|
GB0004887D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004890D0
(en)
*
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004886D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
GB0004888D0
(en)
|
2000-03-01 |
2000-04-19 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7087608B2
(en)
|
2000-03-03 |
2006-08-08 |
Robert Charles Atkins |
Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
|
GB0007371D0
(en)
|
2000-03-28 |
2000-05-17 |
Astrazeneca Uk Ltd |
Chemical compounds
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
PT1315715E
(pt)
|
2000-08-18 |
2008-10-30 |
Millennium Pharm Inc |
Derivados de quianazolina utilizados como inibidores de quinase
|
GB0022438D0
(en)
|
2000-09-13 |
2000-11-01 |
Novartis Ag |
Organic Compounds
|
PL209733B1
(pl)
*
|
2000-10-27 |
2011-10-31 |
Novartis Ag |
Zastosowanie 4-(4-metylopiperazyno-1-ylometylo)-N-[4-metylo-3-(4-pirydyn-3-ylo)pirymidyn-2-yloamino)fenylo]benzamidu w leczeniu żołądkowo-jelitowych guzów podścieliskowych
|
AU2002217999A1
(en)
|
2000-11-01 |
2002-05-15 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
GB0103926D0
(en)
*
|
2001-02-17 |
2001-04-04 |
Astrazeneca Ab |
Chemical compounds
|
ES2640787T3
(es)
|
2001-02-19 |
2017-11-06 |
Novartis Ag |
Combinación de un derivado de rapamicina y letrozol para tratar el cáncer de mama
|
SE0100569D0
(sv)
*
|
2001-02-20 |
2001-02-20 |
Astrazeneca Ab |
New compounds
|
CN1511036B
(zh)
|
2001-02-27 |
2010-05-05 |
诺瓦提斯公司 |
包含信号转导抑制剂和埃坡霉素衍生物的联合形式
|
PL392652A1
(pl)
|
2001-05-16 |
2010-12-06 |
Novartis Ag |
Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
|
ATE331519T1
(de)
*
|
2001-05-16 |
2006-07-15 |
Gpc Biotech Ag |
Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
|
AU2002345670A1
(en)
|
2001-06-14 |
2003-01-02 |
The Regents Of The University Of California |
Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
|
WO2003000186A2
(en)
|
2001-06-21 |
2003-01-03 |
Ariad Pharmaceuticals, Inc. |
Novel phenylamino-pyrimidines and uses thereof
|
WO2003000687A1
(en)
|
2001-06-22 |
2003-01-03 |
Merck & Co., Inc. |
Tyrosine kinase inhibitors
|
CA2452371A1
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating allergic diseases
|
EP1401416B1
(en)
|
2001-06-29 |
2006-10-25 |
AB Science |
Use of c-kit inhibitors for treating inflammatory bowel diseases (ibd)
|
WO2003002108A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating inflammatory diseases
|
WO2003003006A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
US20040266797A1
(en)
*
|
2001-06-29 |
2004-12-30 |
Alain Moussy |
Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
|
EP1427422A1
(en)
*
|
2001-09-20 |
2004-06-16 |
AB Science |
Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
|
WO2003040141A1
(en)
*
|
2001-09-28 |
2003-05-15 |
Bayer Pharmaceuticals Corporation |
Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
|
ATE434038T1
(de)
|
2001-10-05 |
2009-07-15 |
Novartis Ag |
Mutierte abl-kinase-domänen
|
GB0201508D0
(en)
|
2002-01-23 |
2002-03-13 |
Novartis Ag |
Organic compounds
|
GB0202874D0
(en)
*
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
GB0202873D0
(en)
|
2002-02-07 |
2002-03-27 |
Novartis Ag |
Organic compounds
|
AU2007203463B2
(en)
*
|
2002-02-07 |
2010-12-23 |
Novartis Pharma Ag |
N-phenyl-2-pyrimidine-amine derivatives
|
WO2003070248A1
(en)
*
|
2002-02-22 |
2003-08-28 |
The Government Of The United States The Department Of Veterans Affairs |
Use of 4-(4-methylpiperazin-1-ylmethyl)-n[4-methyl-3-(4-pyridin-3-yl) pyrimidin-2-ylamino) phenyl]-benzamide for treating seminomas
|
CA2477111A1
(en)
*
|
2002-02-27 |
2003-09-04 |
Ab Science |
Use of tyrosine kinase inhibitors for treating cns disorders
|
DE60323613D1
(de)
*
|
2002-02-27 |
2008-10-30 |
Ab Science |
Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch
|
RU2341266C2
(ru)
*
|
2002-02-28 |
2008-12-20 |
Новартис Аг |
Стенты с нанесенным покрытием, содержащим n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3-пиридил)-2-пиримидинамин
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
GB0209265D0
(en)
*
|
2002-04-23 |
2002-06-05 |
Novartis Ag |
Organic compounds
|
WO2003095448A1
(en)
*
|
2002-05-06 |
2003-11-20 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
NZ560662A
(en)
|
2002-05-16 |
2009-09-25 |
Novartis Ag |
Use of EDG receptor binding agents in cancer
|
WO2004000318A2
(en)
|
2002-06-21 |
2003-12-31 |
Cellular Genomics, Inc. |
Certain amino-substituted monocycles as kinase modulators
|
US20060052387A1
(en)
*
|
2002-06-26 |
2006-03-09 |
Marsh Clay B |
Organic compounds
|
DK1533304T3
(da)
*
|
2002-06-28 |
2010-03-22 |
Nippon Shinyaku Co Ltd |
Amidderivat
|
GB0215676D0
(en)
*
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US6872724B2
(en)
|
2002-07-24 |
2005-03-29 |
Merck & Co., Inc. |
Polymorphs with tyrosine kinase activity
|
JP4726486B2
(ja)
*
|
2002-08-02 |
2011-07-20 |
アブ サイエンス |
2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法
|
GB0222514D0
(en)
|
2002-09-27 |
2002-11-06 |
Novartis Ag |
Organic compounds
|
US7879868B2
(en)
*
|
2002-10-11 |
2011-02-01 |
Novartis Ag |
Use of imatinib (glivec,sti-571) to inhibit breast cancer resistance protein (BCRP)-mediated resistance to therapeutic agents
|
GB0224455D0
(en)
*
|
2002-10-21 |
2002-11-27 |
Novartis Ag |
Organic compounds
|
US7094785B1
(en)
|
2002-12-18 |
2006-08-22 |
Cornell Research Foundation, Inc. |
Method of treating polycythemia vera
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
GB2398565A
(en)
|
2003-02-18 |
2004-08-25 |
Cipla Ltd |
Imatinib preparation and salts
|
JP2006513791A
(ja)
*
|
2003-04-04 |
2006-04-27 |
ベイコ テック リミテッド |
血管用ステント
|
WO2004099186A1
(en)
|
2003-05-06 |
2004-11-18 |
Il Yang Pharm Co., Ltd. |
N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
|
MY150088A
(en)
|
2003-05-19 |
2013-11-29 |
Irm Llc |
Immunosuppressant compounds and compositions
|
CA2524048C
(en)
|
2003-05-19 |
2013-06-25 |
Irm Llc |
Immunosuppressant compounds and compositions
|
DE602004022540D1
(de)
*
|
2003-05-27 |
2009-09-24 |
Robert P Haegerkvist |
Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes
|
CN1805748B
(zh)
*
|
2003-06-13 |
2010-05-26 |
诺瓦提斯公司 |
作为raf激酶抑制剂的2-氨基嘧啶衍生物
|
BRPI0413977A
(pt)
|
2003-08-27 |
2006-11-07 |
Osi Eyetech Inc |
método para suprimir um distúrbio neovascular, e para tratar um paciente diagnosticado com ou em risco de desenvolver um distúrbio neovascular, composição farmacêutica, e, embalagem farmacêutica
|
CN101693031A
(zh)
|
2003-11-18 |
2010-04-14 |
诺瓦提斯公司 |
Kit突变形式的抑制剂
|
US7728131B2
(en)
*
|
2003-12-25 |
2010-06-01 |
Nippon Shinyaku Co., Ltd. |
Amide derivative and medicine
|
EP1725295B1
(en)
*
|
2004-01-21 |
2010-09-15 |
Emory University |
Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
|
AR047530A1
(es)
|
2004-02-04 |
2006-01-25 |
Novartis Ag |
Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-(4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil)-benzamida
|
PT1720853E
(pt)
|
2004-02-11 |
2016-03-04 |
Natco Pharma Ltd |
Nova forma polimórfica de mesilato de imatinib e processo para a sua preparação
|
CN1309719C
(zh)
*
|
2004-02-18 |
2007-04-11 |
陈国庆 |
苯氨基嘧啶衍生物及其用途
|
KR20080083220A
(ko)
|
2004-04-07 |
2008-09-16 |
노파르티스 아게 |
Iap 억제제
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
EP1786781A2
(en)
*
|
2004-08-27 |
2007-05-23 |
GPC Biotech AG |
Pyrimidine derivatives
|
TR200701870T1
(tr)
|
2004-09-02 |
2007-05-21 |
Cipla Limited |
İmatinib mesilatın kararlı kristal formu ve bu formun hazırlanması için işlem.
|
US8735415B2
(en)
|
2004-09-09 |
2014-05-27 |
Natco Pharma Limited |
Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
CA2591321C
(en)
|
2004-09-09 |
2013-09-24 |
Natco Pharma Limited |
Phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
|
US7939541B2
(en)
|
2004-09-09 |
2011-05-10 |
Natco Pharma Limited |
Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
|
WO2006054314A1
(en)
*
|
2004-11-17 |
2006-05-26 |
Natco Pharma Limited |
Polymorphic forms of imatinib mesylate
|
DE602005023658D1
(de)
*
|
2004-12-30 |
2010-10-28 |
Inst Farmaceutyczny |
Verfahren zur herstellung von imatinib-base
|
CN1939910A
(zh)
*
|
2004-12-31 |
2007-04-04 |
孙飘扬 |
氨基嘧啶类化合物及其盐和其制备方法与药物用途
|
CN1972917B
(zh)
*
|
2004-12-31 |
2010-08-25 |
孙飘扬 |
氨基嘧啶类化合物及其盐和其制备方法与药物用途
|
AU2006207321B2
(en)
|
2005-01-21 |
2012-09-06 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
BRPI0609296A2
(pt)
|
2005-05-02 |
2010-03-23 |
Novartis Ag |
uso de derivados de pirimidilaminobenzamida para o tratamento de mastocitose sistÊmica
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
UA96139C2
(xx)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)$антитело к нейропилину-1 (nrp1)
|
BRPI0618808A2
(pt)
|
2005-11-21 |
2011-09-13 |
Novartis Ag |
uso de um inibidor de mtor
|
CA2824307C
(en)
|
2005-11-25 |
2016-03-29 |
Novartis Ag |
F, g, h, i and k crystal forms of imatinib mesylate
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
WO2007124252A2
(en)
|
2006-04-05 |
2007-11-01 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
CA2644143C
(en)
|
2006-04-05 |
2013-10-01 |
Novartis Ag |
Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
CN101443002B
(zh)
|
2006-05-09 |
2012-03-21 |
诺瓦提斯公司 |
包含铁螯合剂和抗肿瘤药的组合及其用途
|
US20060223817A1
(en)
*
|
2006-05-15 |
2006-10-05 |
Chemagis Ltd. |
Crystalline imatinib base and production process therefor
|
WO2007138705A1
(ja)
|
2006-06-01 |
2007-12-06 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
発がん抑制剤
|
JP2010504933A
(ja)
|
2006-09-29 |
2010-02-18 |
ノバルティス アーゲー |
Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
JP2009514988A
(ja)
*
|
2006-10-26 |
2009-04-09 |
シコール インコーポレイティド |
イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
|
US8168787B2
(en)
|
2006-11-16 |
2012-05-01 |
F.I.S. Fabbrica Italiana Sintetici S.P.A. |
Process for the preparation of imatinib and intermediates thereof
|
CN101245061B
(zh)
*
|
2007-02-13 |
2012-09-19 |
天津天士力集团有限公司 |
N-(5-氨基-2-甲基苯基)-4-(3-吡啶基)-2-嘧啶胺类一氧化氮供体型衍生物,制备方法及其用途
|
CN101626758A
(zh)
|
2007-02-15 |
2010-01-13 |
诺瓦提斯公司 |
用于治疗癌症的lbh589和其他治疗剂的组合
|
RU2329260C1
(ru)
*
|
2007-02-20 |
2008-07-20 |
Юрий Иосифович Копырин |
Способ получения 2-анилинопиримидинов или их солей (варианты)
|
JP2010521477A
(ja)
*
|
2007-03-12 |
2010-06-24 |
ドクター レディズ ラボラトリーズ リミテッド |
イマチニブメシレート
|
WO2008117298A1
(en)
*
|
2007-03-26 |
2008-10-02 |
Natco Pharma Limited |
A novel method of preparation of imatinib
|
US7550591B2
(en)
|
2007-05-02 |
2009-06-23 |
Chemagis Ltd. |
Imatinib production process
|
WO2008136010A1
(en)
*
|
2007-05-07 |
2008-11-13 |
Natco Pharma Limited |
A process for the preparation of highly pure imatinib base
|
WO2008153974A1
(en)
|
2007-06-07 |
2008-12-18 |
Intra-Cellular Therapies, Inc. |
Novel heterocycle compounds and uses thereof
|
US8367686B2
(en)
|
2007-06-07 |
2013-02-05 |
Intra-Cellular Therapies, Inc. |
Heterocycle compounds and uses thereof
|
ES2535166T3
(es)
*
|
2007-09-04 |
2015-05-06 |
The Scripps Research Institute |
Pirimidinil-aminas sustituidas como inhibidores de proteína-quinasas
|
WO2009060463A1
(en)
*
|
2007-11-05 |
2009-05-14 |
Natco Pharma Limited |
An environmentally friendly process for the preparation of imatinib base
|
EP2062885A1
(en)
*
|
2007-11-21 |
2009-05-27 |
Eczacibasi-Zentiva Kimyasal Ürünler Sanayi ve Ticaret A.S. |
Acid addition salts of imatinib and formulations comprising the same
|
DK2252597T3
(da)
*
|
2008-02-01 |
2014-04-28 |
Akinion Pharmaceuticals Ab |
Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer
|
CA2719457C
(en)
|
2008-03-24 |
2017-05-02 |
Novartis Ag |
Arylsulfonamide-based matrix metalloprotease inhibitors
|
AU2009228778B2
(en)
|
2008-03-26 |
2012-04-19 |
Novartis Ag |
Hydroxamate-based inhibitors of deacetylases B
|
ES2645689T3
(es)
|
2008-05-21 |
2017-12-07 |
Ariad Pharmaceuticals, Inc. |
Derivados de fósforo como inhibidores de quinasas
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
CN101584696A
(zh)
|
2008-05-21 |
2009-11-25 |
上海艾力斯医药科技有限公司 |
包含喹唑啉衍生物的组合物及制备方法、用途
|
PL215042B1
(pl)
*
|
2008-08-01 |
2013-10-31 |
Temapharm Spolka Z Ograniczona Odpowiedzialnoscia |
Sposób wytwarzania imatinibu
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MY164581A
(en)
|
2008-08-15 |
2018-01-15 |
Boehringer Ingelheim Int |
Purin derivatives for use in the treatment of fab-related diseases
|
SI2350129T1
(sl)
|
2008-08-25 |
2015-11-30 |
Amplimmune, Inc. |
Sestavki PD-1 antagonistov in postopek njihove uporabe
|
US20110223241A1
(en)
|
2008-10-16 |
2011-09-15 |
Celator Pharmaceuticals, Inc. |
Combination methods and compositions
|
EP2186514B1
(en)
|
2008-11-14 |
2016-06-29 |
Kinki University |
Treatment of Malignant Peripheral Nerve Sheath Tumors
|
US8486930B2
(en)
|
2008-12-18 |
2013-07-16 |
Novartis Ag |
Salts
|
WO2010080409A1
(en)
|
2008-12-18 |
2010-07-15 |
Novartis Ag |
Hemifumarate salt of 1- [4- [1- ( 4 -cyclohexyl-3 -trifluoromethyl-benzyloxyimino ) -ethyl] -2 -ethyl-benzyl] -a zetidine-3-carboxylic acid
|
US8173634B2
(en)
|
2008-12-18 |
2012-05-08 |
Novartis Ag |
Polymorphic form of 1-(4-{1-[(E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino]-ethyl}-2-ethyl-benzyl)-azetidine-3-carboxylic
|
US8865729B2
(en)
|
2008-12-23 |
2014-10-21 |
Boehringer Ingelheim International Gmbh |
Salt forms of a xanthine compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
TW201031406A
(en)
|
2009-01-29 |
2010-09-01 |
Novartis Ag |
Substituted benzimidazoles for the treatment of astrocytomas
|
AR075204A1
(es)
|
2009-01-29 |
2011-03-16 |
Boehringer Ingelheim Int |
Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
|
JP2012517977A
(ja)
|
2009-02-13 |
2012-08-09 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害剤(リナグリプチン)を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
|
EP2400985A2
(en)
|
2009-02-25 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
|
WO2010099364A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519281A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
UA103918C2
(xx)
|
2009-03-02 |
2013-12-10 |
Айерем Элелси |
N-(гетеро)арил, 2-(гетеро)арилзаміщені ацетаміди для застосування як модуляторів wnt передачі сигналу$n-(гетеро)арил, 2-(гетеро)арилзамещенные ацетамиды для применения как модуляторов wnt передачи сигнала
|
TW201102068A
(en)
|
2009-06-02 |
2011-01-16 |
Novartis Ag |
Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
|
CA2765983C
(en)
|
2009-06-26 |
2017-11-14 |
Novartis Ag |
1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
|
WO2011014520A2
(en)
|
2009-07-29 |
2011-02-03 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
MX2012001838A
(es)
|
2009-08-12 |
2012-02-29 |
Novartis Ag |
Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion.
|
CA2771532C
(en)
|
2009-08-17 |
2021-03-23 |
Intellikine, Inc. |
Heterocyclic compounds and uses thereof
|
BR112012008061A2
(pt)
|
2009-08-20 |
2016-03-01 |
Novartis Ag |
compostos de oxima heterocíclica
|
WO2011023677A1
(en)
|
2009-08-26 |
2011-03-03 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
EP2475668A1
(en)
|
2009-09-10 |
2012-07-18 |
Novartis AG |
Ether derivatives of bicyclic heteroaryls
|
PT2482812T
(pt)
|
2009-10-02 |
2023-01-24 |
Boehringer Ingelheim Int |
Composições farmacêuticas compreendendo bi-1356 e metformina
|
WO2011044001A1
(en)
|
2009-10-09 |
2011-04-14 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
PL389357A1
(pl)
|
2009-10-22 |
2011-04-26 |
Tomasz Koźluk |
Sole imatinibu z pochodnymi kwasów winowych i sposób ich wytwarzania
|
JP5466767B2
(ja)
|
2009-11-04 |
2014-04-09 |
ノバルティス アーゲー |
Mek阻害剤として有用なヘテロ環式スルホンアミド誘導体
|
JP6220126B2
(ja)
|
2009-11-23 |
2017-10-25 |
セルリアン・ファーマ・インコーポレイテッド |
治療的送達のためのシクロデキストリンに基づく重合体
|
JP2013512215A
(ja)
|
2009-11-25 |
2013-04-11 |
ノバルティス アーゲー |
二環式ヘテロアリールのベンゼン縮合6員酸素含有ヘテロ環誘導体
|
AU2010323068B2
(en)
|
2009-11-27 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin
|
US8394858B2
(en)
|
2009-12-03 |
2013-03-12 |
Novartis Ag |
Cyclohexane derivatives and uses thereof
|
EP2509964B1
(en)
|
2009-12-08 |
2014-04-30 |
Novartis AG |
Heterocyclic sulfonamide derivatives
|
EP2509973A1
(en)
|
2009-12-10 |
2012-10-17 |
Arch Pharmalabs Limited |
Process for the preparation of imatinib and salts thereof
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
WO2011090940A1
(en)
|
2010-01-19 |
2011-07-28 |
Cerulean Pharma Inc. |
Cyclodextrin-based polymers for therapeutic delivery
|
WO2011099039A1
(en)
|
2010-02-15 |
2011-08-18 |
Reliance Life Sciences Pvt. Ltd. |
Process for the preparation of alpha form of imatinib mesylate
|
PL390611A1
(pl)
|
2010-03-04 |
2011-09-12 |
Tomasz Koźluk |
Sposób otrzymywania polimorficznej formy alfa i nowa forma polimorficzna mesylanu imatinibu
|
WO2011114337A1
(en)
|
2010-03-15 |
2011-09-22 |
Natco Pharma Limited |
Process for the preparation of highly pure crystalline imatinib base
|
JP2013522279A
(ja)
|
2010-03-18 |
2013-06-13 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病及び関連状態の治療で用いるgpr119作動薬とddp−iv阻害薬リナグリプチンの組合せ
|
US20110237686A1
(en)
|
2010-03-26 |
2011-09-29 |
Cerulean Pharma Inc |
Formulations and methods of use
|
WO2011130918A1
(zh)
*
|
2010-04-23 |
2011-10-27 |
上海百灵医药科技有限公司 |
一种伊马替尼的合成方法
|
EP2382976A1
(en)
|
2010-04-30 |
2011-11-02 |
Hiroshima University |
Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
WO2011157793A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
WO2011157787A1
(en)
|
2010-06-17 |
2011-12-22 |
Novartis Ag |
Biphenyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
WO2011157450A1
(en)
|
2010-06-18 |
2011-12-22 |
Krka, D. D., Novo Mesto |
New polymorphic form of imatinib base and preparation of salts thereof
|
WO2011160798A1
(en)
|
2010-06-21 |
2011-12-29 |
Zaklady Farmaceutyczne Polpharma Sa |
Pharmaceutical compositions comprising imatinib or pharmaceutically acceptable salt thereof and processes for the manufacture thereof
|
MX2012014247A
(es)
|
2010-06-24 |
2013-01-18 |
Boehringer Ingelheim Int |
Terapia para la diabetes.
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
MX2013000083A
(es)
|
2010-07-09 |
2013-02-26 |
Genentech Inc |
Anticuerpos de anti-neuropilina y metodos de uso.
|
US8697739B2
(en)
|
2010-07-29 |
2014-04-15 |
Novartis Ag |
Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
|
RU2013110058A
(ru)
|
2010-08-11 |
2014-09-20 |
Синтон Б.В. |
Фармацевтический гранулят, содержащий иматиниба мезилат
|
TR201007005A2
(tr)
|
2010-08-23 |
2011-09-21 |
Mustafa Nevzat İlaç Sanayi̇i̇ A.Ş. |
İmatinib baz üretim yöntemi
|
US8946260B2
(en)
|
2010-09-16 |
2015-02-03 |
Novartis Ag |
17α-hydroxylase/C17,20-lyase inhibitors
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
TR201010618A2
(tr)
|
2010-12-20 |
2012-07-23 |
Bi̇lgi̇ç Mahmut |
İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
|
CN103270026A
(zh)
|
2010-12-21 |
2013-08-28 |
诺瓦提斯公司 |
作为vps34抑制剂的联-杂芳基化合物
|
WO2012090221A1
(en)
|
2010-12-29 |
2012-07-05 |
Cadila Healthcare Limited |
Novel salts of imatinib
|
WO2012107500A1
(en)
|
2011-02-10 |
2012-08-16 |
Novartis Ag |
[1, 2, 4] triazolo [4, 3 -b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
JP5808826B2
(ja)
|
2011-02-23 |
2015-11-10 |
インテリカイン, エルエルシー |
複素環化合物およびその使用
|
CZ305457B6
(cs)
|
2011-02-28 |
2015-09-30 |
Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. |
Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
|
US20130338152A1
(en)
|
2011-03-08 |
2013-12-19 |
Irm Llc |
Fluorophenyl bicyclic heteroaryl compounds
|
PL394169A1
(pl)
|
2011-03-09 |
2012-09-10 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
|
EP2508525A1
(en)
|
2011-04-05 |
2012-10-10 |
Bayer Pharma Aktiengesellschaft |
Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
|
JP2014519813A
(ja)
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用
|
BR112013027395A2
(pt)
|
2011-04-28 |
2017-01-17 |
Novartis Ag |
inibidores de 17alfa-hidroxilase/c17,20-liase
|
EA201391626A1
(ru)
|
2011-05-04 |
2014-03-31 |
Ариад Фармасьютикалз, Инк. |
Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
|
CN102796110B
(zh)
*
|
2011-05-23 |
2016-03-30 |
复旦大学 |
苯胺嘧啶化合物及其制备方法和用途
|
BR112013031201A2
(pt)
|
2011-06-09 |
2017-01-31 |
Novartis Ag |
derivados de sulfonamida heterocíclicos, composição farmacêutica os compreendendo, uso, processo para a fabricação de (r)-n-(4,5-difluoro-6-((2-fluoro-4-iodofenil)amino)benzofuran-7-il)-1-(2,3-di-idroxipropil)ciclopropano-5 1-sulfonamida e kit
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
US8859535B2
(en)
|
2011-06-20 |
2014-10-14 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
US9750700B2
(en)
|
2011-06-22 |
2017-09-05 |
Natco Pharma Limited |
Imatinib mesylate oral pharmaceutical composition and process for preparation thereof
|
EP2723740A1
(en)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Solid forms and salts of tetrahydro-pyrido-pyrimidine derivatives
|
ITMI20111309A1
(it)
|
2011-07-14 |
2013-01-15 |
Italiana Sint Spa |
Procedimento di preparazione di imatinib mesilato
|
MX366629B
(es)
|
2011-07-15 |
2019-07-17 |
Boehringer Ingelheim Int |
Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
|
WO2013035102A1
(en)
|
2011-09-05 |
2013-03-14 |
Natco Pharma Limited |
Processes for the preparation of imatinib base and intermediates thereof
|
CA2848809A1
(en)
|
2011-09-15 |
2013-03-21 |
Novartis Ag |
6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase
|
EP2776035B1
(en)
|
2011-11-01 |
2016-08-10 |
Modgene, Llc |
Compositions and methods for reduction of amyloid-beta load
|
RU2486180C1
(ru)
*
|
2011-11-02 |
2013-06-27 |
Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") |
Способ получения 2-ариламино-4-гетарилпиримидинов
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
US9408885B2
(en)
|
2011-12-01 |
2016-08-09 |
Vib Vzw |
Combinations of therapeutic agents for treating melanoma
|
CN103159739A
(zh)
*
|
2011-12-09 |
2013-06-19 |
天津市国际生物医药联合研究院有限公司 |
1,4-二取代-1,2,3-三氮唑类化合物及其制备方法
|
JP5903499B2
(ja)
|
2011-12-22 |
2016-04-13 |
ノバルティス アーゲー |
ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
|
EP2794594A1
(en)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Quinoline derivatives
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
WO2013096055A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
BR112014015339A2
(pt)
|
2011-12-23 |
2017-06-13 |
Novartis Ag |
compostos para inibição da interação de bcl2 com parceiros de ligação
|
AU2012355623A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
MX2014007729A
(es)
|
2011-12-23 |
2015-01-12 |
Novartis Ag |
Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
PL226174B1
(pl)
|
2011-12-30 |
2017-06-30 |
Inst Farm |
Polaczenie analogu witaminy D z imatinibem do stosowania w leczeniu skojarzonym niedrobnokomorkowego raka pluc
|
UY34591A
(es)
|
2012-01-26 |
2013-09-02 |
Novartis Ag |
Compuestos de imidazopirrolidinona
|
WO2013120852A1
(en)
|
2012-02-13 |
2013-08-22 |
Grindeks, A Joint Stock Company |
Intermediates for a novel process of preparing imatinib and related tyrosine kinase inhibitors
|
WO2013136141A1
(en)
|
2012-03-13 |
2013-09-19 |
Fresenius Kabi Oncology Ltd. |
An improved process for the preparation of alpha form of imatinib mesylate
|
AU2013243097A1
(en)
|
2012-04-03 |
2014-10-09 |
Novartis Ag |
Combination products with tyrosine kinase inhibitors and their use
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
AU2013253539A1
(en)
|
2012-04-24 |
2014-11-13 |
Chugai Seiyaku Kabushiki Kaisha |
Benzamide derivative
|
KR20150003849A
(ko)
|
2012-04-24 |
2015-01-09 |
추가이 세이야쿠 가부시키가이샤 |
퀴나졸린디온 유도체
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
JP6224084B2
(ja)
|
2012-05-14 |
2017-11-01 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
EP2854812A1
(en)
|
2012-05-24 |
2015-04-08 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
JP6171003B2
(ja)
|
2012-05-24 |
2017-07-26 |
ノバルティス アーゲー |
ピロロピロリジノン化合物
|
CN104582732A
(zh)
|
2012-06-15 |
2015-04-29 |
布里格姆及妇女医院股份有限公司 |
治疗癌症的组合物及其制造方法
|
WO2014016848A2
(en)
|
2012-07-24 |
2014-01-30 |
Laurus Labs Private Limited |
Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
|
WO2014025395A1
(en)
|
2012-08-06 |
2014-02-13 |
Duke University |
Compounds and methods for targeting hsp90
|
WO2014041551A1
(en)
|
2012-09-14 |
2014-03-20 |
Natco Pharma Limited |
Formulation comprising imatinib as oral solution
|
CN103664787B
(zh)
|
2012-09-17 |
2015-09-09 |
南京圣和药业股份有限公司 |
炔杂芳环化合物及其应用
|
WO2014052619A1
(en)
|
2012-09-27 |
2014-04-03 |
Irm Llc |
Piperidine derivatives and compositions as modulators of gpr119 activity
|
US20150238488A1
(en)
|
2012-09-28 |
2015-08-27 |
Hangzhou Bensheng Pharmaceutical Co., Ltd. |
Drug composition for treating tumors and application thereof
|
JP6945963B2
(ja)
*
|
2012-10-04 |
2021-10-06 |
インヒビカーセ セラピューティクス,インコーポレーテッド |
新規な化合物、それらの調製及びそれらの使用
|
CN110787285A
(zh)
|
2012-11-05 |
2020-02-14 |
达纳-法伯癌症研究所股份有限公司 |
Xbp1、cd138和cs1肽、包括所述肽的药物组合物及使用所述肽和组合物的方法
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
CN103848812B
(zh)
*
|
2012-12-04 |
2016-08-03 |
北大方正集团有限公司 |
精制伊马替尼的方法
|
CN103044394A
(zh)
*
|
2012-12-20 |
2013-04-17 |
北京理工大学 |
一种苯基氨基嘧啶衍生物及其制备方法和用途
|
EP2749271A1
(en)
|
2012-12-31 |
2014-07-02 |
Deva Holding Anonim Sirketi |
Optimized manufacturing method and pharmaceutical formulation of imatinib
|
EP2948451B1
(en)
|
2013-01-22 |
2017-07-12 |
Novartis AG |
Substituted purinone compounds
|
EP2948453B1
(en)
|
2013-01-22 |
2017-08-02 |
Novartis AG |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
|
WO2014124860A1
(en)
|
2013-02-14 |
2014-08-21 |
Boehringer Ingelheim International Gmbh |
Specific pde4b-inhibitors for the treatment of diabetes mellitus
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
ES2760023T3
(es)
|
2013-02-20 |
2020-05-12 |
Univ Pennsylvania |
Tratamiento del cáncer utilizando receptor de antígeno quimérico anti-EGFRvIII humanizado
|
EP2968344A1
(en)
|
2013-03-15 |
2016-01-20 |
Boehringer Ingelheim International GmbH |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
JP2016512835A
(ja)
|
2013-03-15 |
2016-05-09 |
インテリカイン, エルエルシー |
キナーゼ阻害剤の組み合わせ及びそれらの使用
|
WO2014155268A2
(en)
|
2013-03-25 |
2014-10-02 |
Novartis Ag |
Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
EP2803353B1
(en)
|
2013-05-14 |
2018-05-23 |
Hetero Research Foundation |
Compositions of Imatinib
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
EP3046563B1
(en)
|
2013-09-22 |
2019-05-29 |
Calitor Sciences, LLC |
Substituted aminopyrimidine compounds as pi3-kinase inhibitors
|
ES2748213T3
(es)
|
2013-10-17 |
2020-03-13 |
Sartar Therapeutics Ltd |
Composiciones que comprenden inhibidores de la fosfodiesterasa para su uso en el tratamiento de un tumor sólido en un paciente humano
|
JP6307088B2
(ja)
|
2013-10-23 |
2018-04-04 |
中外製薬株式会社 |
キナゾリノンおよびイソキノリノン誘導体
|
TW201605450A
(zh)
|
2013-12-03 |
2016-02-16 |
諾華公司 |
Mdm2抑制劑與BRAF抑制劑之組合及其用途
|
WO2015148714A1
(en)
|
2014-03-25 |
2015-10-01 |
Duke University |
Heat shock protein 70 (hsp-70) receptor ligands
|
WO2015145388A2
(en)
|
2014-03-27 |
2015-10-01 |
Novartis Ag |
Methods of treating colorectal cancers harboring upstream wnt pathway mutations
|
CA2943979A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
MX2016012893A
(es)
|
2014-04-03 |
2017-05-12 |
Invictus Oncology Pvt Ltd |
Sustancias terapéuticas combinadas supramoleculares.
|
EP2927223B1
(en)
|
2014-04-04 |
2016-06-29 |
F.I.S.- Fabbrica Italiana Sintetici S.p.A. |
Process for preparing imatinib and salts thereof, free of genotoxic impurity f
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
EP3174869B1
(en)
|
2014-07-31 |
2020-08-19 |
Novartis AG |
Combination therapy of a met inhibitor and an egfr inhibitor
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
CN105585556A
(zh)
*
|
2014-11-13 |
2016-05-18 |
连云港杰瑞药业有限公司 |
一种伊马替尼的合成方法
|
WO2017044434A1
(en)
|
2015-09-11 |
2017-03-16 |
Sunshine Lake Pharma Co., Ltd. |
Substituted heteroaryl compounds and methods of use
|
EP3407874B1
(en)
|
2016-01-25 |
2024-05-22 |
KRKA, d.d., Novo mesto |
Fast dispersible pharmaceutical composition comprising tyrosine-kinase inhibitor
|
DK3240538T3
(da)
|
2016-03-25 |
2021-12-06 |
Ab Science |
Anvendelse af masitinib til behandling af en underpopulation af patienter med amyotrofisk lateralsklerose
|
WO2017184956A1
(en)
|
2016-04-22 |
2017-10-26 |
Duke University |
Compounds and methods for targeting hsp90
|
US10155000B2
(en)
|
2016-06-10 |
2018-12-18 |
Boehringer Ingelheim International Gmbh |
Medical use of pharmaceutical combination or composition
|
EP3257499A1
(en)
|
2016-06-17 |
2017-12-20 |
Vipharm S.A. |
Process for preparation of imatinib methanesulfonate capsules
|
CN107652269A
(zh)
*
|
2016-07-26 |
2018-02-02 |
江苏豪森药业集团有限公司 |
甲磺酸氟马替尼中间体纯化方法
|
WO2018039203A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating multiple myeloma
|
WO2018039205A1
(en)
|
2016-08-23 |
2018-03-01 |
Oncopep, Inc. |
Peptide vaccines and durvalumab for treating breast cancer
|
CN107805240A
(zh)
*
|
2016-09-08 |
2018-03-16 |
中国科学院合肥物质科学研究院 |
一种新型的pdgfr激酶抑制剂及其用途
|
MX2019003489A
(es)
|
2016-09-27 |
2020-01-23 |
Cero Therapeutics Inc |
Moleculas del receptor de envolvimiento quimerico.
|
US10207998B2
(en)
|
2016-09-29 |
2019-02-19 |
Duke University |
Substituted benzimidazole and substituted benzothiazole inhibitors of transforming growth factor-β kinase and methods of use thereof
|
US10927083B2
(en)
|
2016-09-29 |
2021-02-23 |
Duke University |
Substituted benzimidazoles as inhibitors of transforming growth factor-β kinase
|
EP3333162A1
(en)
|
2016-12-12 |
2018-06-13 |
Silesian Catalysts sp. z o.o. |
Metod for preparing n-(2-methyl-5-nitrophenyl)-4-(pyridin-3-yl)pyrimidin-2-amine
|
CN107089969B
(zh)
*
|
2017-04-26 |
2020-04-24 |
黑龙江鑫创生物科技开发有限公司 |
一种合成伊马替尼中间体的方法
|
WO2019067328A1
(en)
|
2017-09-26 |
2019-04-04 |
Cero Therapeutics, Inc. |
CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE
|
WO2019083962A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE AND PEMBROLIZUMAB VACCINES FOR THE TREATMENT OF BREAST CANCER
|
WO2019083960A1
(en)
|
2017-10-24 |
2019-05-02 |
Oncopep, Inc. |
PEPTIDE VACCINES AND HDAC INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
US10751339B2
(en)
|
2018-01-20 |
2020-08-25 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
US20210023135A1
(en)
|
2018-03-28 |
2021-01-28 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
WO2019191334A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
EP3774869A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
MX2021000555A
(es)
|
2018-07-17 |
2021-03-29 |
Boehringer Ingelheim Int |
Tratamiento antidiabetico cardiovascular seguro.
|
WO2020016230A1
(en)
|
2018-07-17 |
2020-01-23 |
Boehringer Ingelheim International Gmbh |
Cardio- and renosafe antidiabetic therapy
|
EP3826988A4
(en)
|
2018-07-24 |
2023-03-22 |
Hygia Pharmaceuticals, LLC |
COMPOUNDS, DERIVATIVES AND ANALOGS AGAINST CANCER
|
AU2020312840A1
(en)
|
2019-07-15 |
2022-01-20 |
Intas Pharmaceuticals Ltd. |
Pharmaceutical composition of imatinib
|
WO2021067875A1
(en)
|
2019-10-03 |
2021-04-08 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
WO2021233534A1
(en)
|
2020-05-20 |
2021-11-25 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021185844A1
(en)
|
2020-03-16 |
2021-09-23 |
Pvac Medical Technologies Ltd |
Use of substance and pharmaceutical composition thereof, and medical treatments or uses thereof
|
WO2021228983A1
(en)
|
2020-05-13 |
2021-11-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
|
WO2022029220A1
(en)
|
2020-08-05 |
2022-02-10 |
Ellipses Pharma Ltd |
Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
BR112023017213A2
(pt)
|
2021-02-26 |
2023-11-21 |
Kelonia Therapeutics Inc |
Vetores lentivirais direcionados a linfócitos
|
WO2023010097A1
(en)
|
2021-07-28 |
2023-02-02 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
WO2024030441A1
(en)
|
2022-08-02 |
2024-02-08 |
National University Corporation Hokkaido University |
Methods of improving cellular therapy with organelle complexes
|